Immunotherapy is the brightest new weapon in fight against cancer. Thank Dr. Steven Rosenberg, who 40 years ago successfully ...

Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...

Explore how E-selectin-targeted polymer-doxorubicin therapy induces regression in colorectal liver metastases.

An expert discusses the next steps for patients with metastatic breast cancer after their disease no longer responds to ...

Cancer metabolism is a critical area of research, central to understanding how malignant tumors manipulate metabolic pathways to support their growth and survival. These alterations not only fuel ...

A phase 2 study for patients with HR-positive, HER2-negative metastatic breast cancer will be evaluating alisertib plus ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne ...

Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer ...

Boston Scientific has signed a deal to acquire the maker of a chemotherapy infusion pump aimed at treating certain inoperable ...